Atossa Therapeutics, Inc. ATOS

Shareholders could be set for a cash reward if the biotech wins a voucher upon approval of (Z)-endoxifen.

Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines in oncology and other areas of significant unmet need, today announced that its Board of Directors has approved a plan to issue one contingent value right ("CVR") for each share of Atossa common stock to enable shareholders to share in a portion of any proceeds received from the monetization of Atossa's first qualifying rare pediatric disease priority r

Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company, today announced that Steven Quay, M.D., Ph.D., Atossa's President and Chief Executive Officer, will participate as a panelist at the 13th Aging Research and Drug Discovery Meeting (ARDD 2026), being held October 1–3, 2026, at the David Rubenstein Treehouse at Harvard University in Boston, MA.

By David Bautz, PhD NASDAQ: ATOS READ THE FULL ATOS RESEARCH REPORT Business Update Atossa Therapeutics, Inc. (NASDAQ: ATOS) is approaching a potentially important inflection point as its two most advanced clinical programs are now fully enrolled and expected to generate data by year-end. The company’s lead asset, (Z)-endoxifen, is being evaluated across multiple potential applications in breast

Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announced its financial results and provided an update on recent corporate developments for the second quarter ended June 30, 2026.

Atossa Therapeutics, Inc. (NASDAQ: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of significant unmet clinical need, today announced the publication of a peer-reviewed preclinical study in npj Breast Cancer evaluating five novel chemical entities structurally related to (Z)-endoxifen. The study titled, "Novel (Z)-endoxifen-related new chemical entities exhibit potent anti-cancer activity in ERα+ breast cancer,

One of Rhode Island's most-wanted fugitives was captured Monday after apparently hiding out for 20 years as a biotech executive.

Atossa Therapeutics, Inc. (NASDAQ: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of significant unmet clinical need, today announced that a poster presentation titled "Dual estrogen receptor and PKC-β signaling modulation by (Z)-Endoxifen: A mechanism-driven therapeutic strategy for estrogen-driven pathology in McCune-Albright Syndrome" was presented at the AACR Special Conference in Cancer Research: Breaking

By David Bautz, PhD NASDAQ: ATOS READ THE FULL ATOS RESEARCH REPORT Business Update Abstracts Presented at ASCO 2026 In June 2026, Atossa Therapeutics, Inc. (NASDAQ: ATOS) announced that two abstracts were presented at the 2026 American Society of Clinical Oncology (ASCO) annual meeting. Both abstracts focused on (Z)-endoxifen and its ongoing clinical development in ER-positive breast cancer.

Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announced the closing of its previously announced registered direct offering of 1,363,637 shares (the "Shares") of its common stock, par value $0.18 per share ("Common Stock") (or common stock equivalents in lieu thereof), Series A warrants to purchase up to 1,363,637 shares of Common Stock and s

Oracle (ORCL) plans to raise about $40 billion via debt and equity issuances in fiscal 2027, includi

Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announced that it has entered into a securities purchase agreement with institutional investors for the purchase and sale of 1,363,638 shares (the "Shares") of its common stock, par value $0.18 per share ("Common Stock") (or common stock equivalents in lieu thereof), Series A warrants to purchase

Atossa Therapeutics CEO Steven Quayjoined Steve Darling from Proactive to discuss the continued advancement of the company’s lead investigational therapy, (Z)-Endoxifen, and its potential applications across multiple breast cancer indications as well as certain rare diseases. The discussion highlighted the scientific foundation of the program, recent clinical data presentations, and key milestones expected in the months ahead. Quay explained that Atossa Therapeutics was founded with a clear mission focused on improving the prevention and treatment of breast cancer. Central to that strategy is

NASDAQ: ATOS David Bautz, PhD: Welcome to the next episode of our CEO Chat series. My name is David Bautz, and I'm a Senior Biotech Analyst here at Zacks Small Cap Research . Joining me today is Dr. Steven Quay. He's the CEO of Atossa Therapeutics (NASDAQ: ATOS). Now, Atossa is a clinical-stage biopharmaceutical company that is developing oral (Z)-endoxifen as a multi-indication endocrine therapy

Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of significant unmet medical need, today announced that two abstracts featuring (Z)-endoxifen have been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, being held May 29 to June 2, 2026 in Chicago, IL.

Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of significant unmet medical need, today announced that it will host a virtual key opinion leader event focused on the evolving clinical and translational data supporting the development of (Z)-endoxifen, the Company's investigational selective estrogen receptor modulator/degrader, or SERM/D, as a potential next-generation endocri

By David Bautz, PhD NASDAQ:ATOS READ THE FULL ATOS RESEARCH REPORT We are initiating coverage of Atossa Therapeutics, Inc. (NASDAQ:ATOS) with a valuation of $22.00. Atossa is a clinical-stage biopharmaceutical company that is repositioning (Z)-endoxifen, an active metabolite of tamoxifen, as a multi-indication endocrine therapy with applications in both rare diseases and oncology. Tamoxifen is a

Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announces its financial results and provides an update on recent corporate developments for the first quarter ended March 31, 2026.